ASX and Media Release

Updated CAVATAK Results to be presented at ESMO 2014 Congress

• Poster presentations to highlight:
  
  o Latest results from the US Phase 2 CALM trial of CAVATAK
  
  o Further results from preclinical studies assessing the combination of CAVATAK with immune checkpoint inhibitors

• Abstracts available online on September 17 with latest results released after the conference poster presentations on September 28 and 29

17 September 2014, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) is pleased to report that there will be two CAVATAK poster presentations at the European Society for Medical Oncology (ESMO) 2014 Congress, in Madrid, Spain, from September 26- 30. The ESMO conference is the largest oncology conference held in Europe, with more than 16,000 expected to attend.

A poster reporting the most recent results from the US Phase 2 CALM trial of CAVATAK™ will be presented by Dr Robert Andtbacka, Lead Study Investigator from the Huntsman Cancer Institute, Utah, as part of the melanoma session on Sunday, 28 September. The poster is entitled:

**CALM study: Secondary endpoints of a Phase II study of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, delivered intratumorally in patients with advanced malignant melanoma.**

An additional poster focusing on the preclinical combination of CAVATAK™ and checkpoint inhibitors will be presented by Dr Darren Shafren, Viralytics, Chief Scientific Officer, in the Immunotherapy of Cancer session on Monday, 29 September. The poster is entitled:

**Combination of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21 and PD-1 blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model.**

The abstracts of these presentations will appear on the ESMO website (www.esmo.org) at 8 pm Sydney time on Wednesday, 17 September, and a link to the presentations will be posted on the Viralytics website (www.viralytics.com) Thursday morning, 18 September.

The data presented in the abstracts reflects the information available at the time of submission in May 2014. The poster presentations will include the most recent data and will
be available on the Viralytics website following the Madrid presentations on September 28 and 29.

Enquiries:
Dr Malcolm McColl  Mr Rudi Michelson
Chief Executive Officer  Monsoon Communications
02 9988 4000  03 9620 3333

About Viralytics Ltd:

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics’ lead investigational product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific ‘receptor’ proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK™’s preferential targeting of cancer cells creates the potential for a more tolerable cancer treatment.

The company has completed enrolment in a single arm Phase 2 clinical trial of intratumourally administered CAVATAK™ in the treatment of Late-stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. The study is being conducted in patients with late stage (IIIC and IV) malignant melanoma.

In addition, Viralytics has commenced a Phase 1/2 trial of CAVATAK™ delivered systemically (intravenously). This trial, referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study, is enrolling patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. The STORM trial is being conducted at three UK cancer centres.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics’ ADRs also trade under VRACY on the US OTCQX International market.